Summary

vacuumquit71 Users

  • Design as well as Consent of your Immune-Based Prognostic Model for Pancreatic Adenocarcinoma Determined by General public Listings.
Offline Offline
Posts:
0 (0 per day)
Age:
N/A
Date Registered:
2025-07-08, 14:39:38
Local Time:
2025-07-19, 05:01:14
Last Active:
2025-07-08, 20:01:12
Signature:
Pharmacokinetic analysis unexpectedly indicated a half-life of 9-19days, invalidating the CIVI dosing resulting in discontinuation of the study before